The worldwide pharmaceutical cold chain logistics industry is vast and continues to grow, with projected global biopharma cold chain logistics spending in 2022 predicted to reach $19.1 billion. And global biopharma cold chain product sales in 2024 are expected to reach $440 billion.
The pandemic accelerated market growth with an increase in temperature-sensitive pharmaceuticals transported across the globe and the continuing requirement for worldwide shipments of COVID-19 therapies, vaccines and boosters.
There are key considerations when selecting suitable shipping solutions for temperature-sensitive payloads, including the type of thermal packaging, insulation and qualified durations. Many companies also wrestle with the question of whether to purchase or rent.
In a recent article in European Pharmaceutical Manufacturer, Paul Terry, Sales and Marketing Director - EMEA, helps answer this question.
